Hot Topics in Thyroid Cancer

References

• AdisInsight. Donafenib - Suzhou Zelgen Biopharmaceuticals. https://adisinsight.springer.com/drugs/800041247. Accessed January 23, 2020.
• Adis Insight. Ponatinib – Takeda. https://adisinsight.springer.com/drugs/800028361. Accessed January 20, 2020.
• CenterWatch. A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer. https://www.centerwatch.com/clinical-trials/listings/152902/a-double-blind-randomized-phase-iii-study-evaluating-the-efficacy-and-safety-of-sorafenib-compared-to-placebo-in-locally-advancedmetastatic-rai-refractory-differentiated-thyroid-cancer-2/?&radius=50&featured=true. Accessed January 23, 2020.
• CenterWatch. Donafenib in 131I-Refractory Differentiated Thyroid Cancer. https://www.centerwatch.com/clinical-trials/listings/209082/differentiated-thyroid-cancer-donafenib-131i-refractory-differentiated-thyroid/?&radius=50. Accessed January 23, 2020.
• CenterWatch. Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer. https://www.centerwatch.com/clinical-trials/listings/190666/differentiated-thyroid-cancer-efficacy-apatinib-radioactive-iodine-refractory/?&radius=50 . Accessed January 23, 2020.
• CenterWatch. UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone. https://www.centerwatch.com/clinical-trials/listings/189567/thyroid-cancer-upcc-36315-phase-ii/?&radius=50. Accessed January 23, 2020.
• Lilly. Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer. https://investor.lilly.com/news-releases/news-release-details/lilly-opens-phase-3-clinical-trial-ret-mutant-medullary-thyroid. Accessed January 23, 2020.
• NIH. Atezolizumab with Chemotherapy in Treating Patients with Anaplastic or Poorly Differentiated Thyroid Cancer. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2019-02581&r=1. Accessed January 20, 2020.
• NIH. Cyclophosphamide and Sirolimus and in Treating Patients with Metastatic, Radioiodine-Refractory Thyroid Cancer. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2017-00759&r=1. Accessed January 20, 2020.
• NIH. Nivolumab and Ipilimumab in Treating Patients with Metastatic or Refractory Thyroid Cancer. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2017-02341&r=1. Accessed January 20, 2020.
• NIH. Pembrolizumab and Docetaxel in Treating Participants with Poorly Chemo-Responsive and Unresectable Thyroid and Salivary Gland Cancers. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2018-00339&r=1. Accessed January 20, 2020.
• NIH. Ponatinib for the Treatment of Advanced and Metastatic Medullary Thyroid Cancer. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2019-05461&r=1. Accessed January 20, 2020.
• NIH. Phase 1 / 2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2017-00300&r=1. Accessed January 20, 2020.
• NIH. Phase 1 / 2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2017-00976&r=1. Accessed January 20, 2020.
• NIH. Regorafenib in Treating Patients with Metastatic Medullary and Differentiated Radioiodine Refractory Thyroid Cancer. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2016-00333&r=1. Accessed January 20, 2020.
• NIH. Sapanisertib in Treating Patients with Newly Diagnosed or Refractory / Metastatic Anaplastic Thyroid Cancer. https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2015-01607&r=1. Accessed January 20, 2020.
• TECENTRIQ. TECENTRIQ atezolizumab. https://www.tecentriq.com/sclc.html?c=pdl-16d97f8fb9c&gclid=EAIaIQobChMIp6KJ39SS5wIViJyzCh0QJg4rEAAYASAAEgInC_D_BwE&gclsrc=aw.ds. Accessed January 20, 2020.